image1

WILLIAM H. MILLER, Ph.D

 William H. Miller, Ph.D., the Principal Consultant at MedChem Innovations, LLC, is an accomplished “drug hunter” with over 29 years of experience in preclinical drug discovery research in the pharmaceutical industry. His credentials include:

  • Strong background in medicinal and synthetic organic chemistry
  • Established track record for successfully advancing initial hits to viable development candidates, and for identifying creative solutions to complex drug discovery challenges
  • Experience in multiple therapeutic areas, including antibacterials, cardiovascular, dermatology, inflammation, neuroscience (pain), oncology, ophthalmology, osteoporosis, and supportive care
  • Experience with multiple target classes, including enzymes (such as bacterial enzymes, epigenetic enzymes, kinases, prolyl hydroxylase, sirtuins, thrombin), receptors, and ion channels
  • Designing molecules for oral, intravenous and topical routes of administration
  • Expertise in externalization/outsourcing of R&D activities, including medicinal chemistry, scale-up chemistry, biology and DMPK, at US and international (China and India) contract research organizations (CROs)
  • Contributed to the identification of 18 development candidates, including the late-stage clinical assets Daprodustat, Gepotidacin, Afabicin and Lotrafiban

Dr. Miller earned a BS in chemistry (with honors) from the University of Connecticut, graduating Magna Cum Laude. He then went on to earn a Ph.D. in synthetic organic chemistry at Yale University, under the direction of Professor Samuel J. Danishefsky. Dr. Miller then moved to Harvard University, where he worked as an NIH postdoctoral fellow for two years in the labs of Professor Yoshito Kishi. Following the completion of his academic studies, Dr. Miller began his industrial career as a medicinal chemist in 1989, initially in the Medical Products Division at DuPont, which later became the DuPont Merck Pharmaceutical Company. In 1991, Dr. Miller moved to SmithKline Beecham Pharmaceuticals, which became GlaxoSmithKline (GSK) in 2000. He worked at GSK for over 27 years before retiring in 2019.